Cargando…
Dihydroartemisinin as a Sensitizing Agent in Cancer Therapies
Cancer is one of the major threats to human health. Although humans have struggled with cancer for decades, the efficacy of treatments for most tumors is still very limited. Dihydroartemisinin (DHA) is a derivative of artemisinin, a first-line antimalarial drug originally developed in China. Beyond...
Autores principales: | Li, Qingrong, Ma, Qiang, Cheng, Jibing, Zhou, Xi, Pu, Wenjie, Zhong, Xiaowu, Guo, Xiaolan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053502/ https://www.ncbi.nlm.nih.gov/pubmed/33880035 http://dx.doi.org/10.2147/OTT.S297785 |
Ejemplares similares
-
Autophagy-dependent cell cycle arrest in esophageal cancer cells exposed to dihydroartemisinin
por: Ma, Qiang, et al.
Publicado: (2020) -
Human Telomerase Reverse Transcriptase as a Therapeutic Target of Dihydroartemisinin for Esophageal Squamous Cancer
por: Li, Qingrong, et al.
Publicado: (2021) -
Dihydroartemisinin inhibits HepG2.2.15 proliferation by inducing cellular senescence and autophagy
por: Zou, Jiang, et al.
Publicado: (2019) -
Comprehensive Analysis of Potential Correlation Between Solute Carrier 1A (SLC1A) Family and Lung Adenocarcinoma
por: Zhong, Xiaowu, et al.
Publicado: (2022) -
Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy
por: Chen, Tao, et al.
Publicado: (2009)